rs9971293
Variant names:
Your query was ambiguous. Multiple possible variants found:
Variant summary
Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_016204.4(GDF2):c.347-28A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0846 in 1,495,310 control chromosomes in the GnomAD database, including 6,849 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.11 ( 1157 hom., cov: 33)
Exomes 𝑓: 0.082 ( 5692 hom. )
Consequence
GDF2
NM_016204.4 intron
NM_016204.4 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.372
Publications
3 publications found
Genes affected
GDF2 (HGNC:4217): (growth differentiation factor 2) This gene encodes a secreted ligand of the TGF-beta (transforming growth factor-beta) superfamily of proteins. Ligands of this family bind various TGF-beta receptors leading to recruitment and activation of SMAD family transcription factors that regulate gene expression. The encoded preproprotein is proteolytically processed to generate each subunit of the disulfide-linked homodimer. This protein regulates cartilage and bone development, angiogenesis and differentiation of cholinergic central nervous system neurons. Mutations in this gene are associated with hereditary hemorrhagic telangiectasia. [provided by RefSeq, Jul 2016]
GDF2 Gene-Disease associations (from GenCC):
- pulmonary arterial hypertensionInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- telangiectasia, hereditary hemorrhagic, type 1Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- telangiectasia, hereditary hemorrhagic, type 5Inheritance: AD, Unknown, AR Classification: MODERATE, LIMITED Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), ClinGen, G2P
- hereditary hemorrhagic telangiectasiaInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.78).
BP6
Variant 10-47324813-A-G is Benign according to our data. Variant chr10-47324813-A-G is described in ClinVar as Benign. ClinVar VariationId is 1296410.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.199 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.108 AC: 16380AN: 152114Hom.: 1153 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
16380
AN:
152114
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.0864 AC: 20507AN: 237432 AF XY: 0.0904 show subpopulations
GnomAD2 exomes
AF:
AC:
20507
AN:
237432
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0820 AC: 110088AN: 1343078Hom.: 5692 Cov.: 19 AF XY: 0.0847 AC XY: 57026AN XY: 673000 show subpopulations
GnomAD4 exome
AF:
AC:
110088
AN:
1343078
Hom.:
Cov.:
19
AF XY:
AC XY:
57026
AN XY:
673000
show subpopulations
African (AFR)
AF:
AC:
6518
AN:
31134
American (AMR)
AF:
AC:
2262
AN:
44362
Ashkenazi Jewish (ASJ)
AF:
AC:
1409
AN:
25078
East Asian (EAS)
AF:
AC:
196
AN:
39098
South Asian (SAS)
AF:
AC:
15155
AN:
83152
European-Finnish (FIN)
AF:
AC:
2957
AN:
48786
Middle Eastern (MID)
AF:
AC:
517
AN:
5550
European-Non Finnish (NFE)
AF:
AC:
76329
AN:
1009384
Other (OTH)
AF:
AC:
4745
AN:
56534
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
5308
10617
15925
21234
26542
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
0
2846
5692
8538
11384
14230
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.108 AC: 16409AN: 152232Hom.: 1157 Cov.: 33 AF XY: 0.108 AC XY: 8016AN XY: 74438 show subpopulations
GnomAD4 genome
AF:
AC:
16409
AN:
152232
Hom.:
Cov.:
33
AF XY:
AC XY:
8016
AN XY:
74438
show subpopulations
African (AFR)
AF:
AC:
8403
AN:
41514
American (AMR)
AF:
AC:
938
AN:
15302
Ashkenazi Jewish (ASJ)
AF:
AC:
198
AN:
3466
East Asian (EAS)
AF:
AC:
42
AN:
5180
South Asian (SAS)
AF:
AC:
861
AN:
4824
European-Finnish (FIN)
AF:
AC:
582
AN:
10616
Middle Eastern (MID)
AF:
AC:
26
AN:
294
European-Non Finnish (NFE)
AF:
AC:
5122
AN:
68010
Other (OTH)
AF:
AC:
213
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
727
1454
2181
2908
3635
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
196
392
588
784
980
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
469
AN:
3478
ClinVar
Significance: Benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
Jun 26, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.